CAR T cell engineering impacts antigen-independent activation and co-inhibition
Viral vectors have successfully modified T cells to express chimeric antigen receptors (CARs), leading to clinical approvals. However, their high cost and regulatory challenges hinder rapid clinical translation. Here, we demonstrate that our lentivirally (LV) manufactured R110-CAR T cells, targeting...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Elsevier
2025-12-01
|
| Seria: | Molecular Therapy: Methods & Clinical Development |
| Hasła przedmiotowe: | |
| Dostęp online: | http://www.sciencedirect.com/science/article/pii/S2329050125001810 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
